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Anh H. Nguyen1,2†, Paul Marsh2†, Lauren Schmiess-Heine2, Peter J. Burke2,3,4, Abraham Lee3,5, Juhyun Lee6 and
Hung Cao2,3,7*Abstract
The purpose of this review is to assess the state-of-the-art fabrication methods, advances in genome editing, and the
use of machine learning to shape the prospective growth in cardiac tissue engineering. Those interdisciplinary emerging
innovations would move forward basic research in this field and their clinical applications. The long-entrenched
challenges in this field could be addressed by novel 3-dimensional (3D) scaffold substrates for cardiomyocyte (CM)
growth and maturation. Stem cell-based therapy through genome editing techniques can repair gene mutation, control
better maturation of CMs or even reveal its molecular clock. Finally, machine learning and precision control for
improvements of the construct fabrication process and optimization in tissue-specific clonal selections with an outlook of
cardiac tissue engineering are also presented.
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The adult mammalian heart is among the least regenera-
tive organs thus cardiomyocytes (CMs) are threatened
by a multitude of factors; such as necrosis, apoptosis,
and oncosis (or ischemic cell death), which may lead to
heart failure [1, 2]. Necrosis, or premature cell death
due to physical or chemical injury, and apoptosis, or
programmed cell death, have more recently been found
to be linked together during pathological states of heart
disease [3]. Regarding cardiac pathogenesis, myocardial
infarction results in scar tissue, regions where CMs are
replaced with fibrillar collagen and/or fibroblast-like
cells [4]. Oncosis, or ischemic cell death, is recognized
as distinct from necrosis in that the cell swells instead of
shrinks, but necrosis and oncosis both follow cell injury
[5]. Heart failure, as of 2017, affected about 38 million
people globally [6], and 6.5 million of those are in the
U.S. alone [7]. Besides heart pathogenesis, the risk of
heart disease rises steadily and sharply with age [8]. All
of these factors compete with the low cell turnover rates© The Author(s). 2019 Open Access This artic
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0.3–1% annually [6]. For these reasons and more, the
heart is one of the most important topics for tissue en-
gineering research. These researches not only would re-
veal mechanism of cardiac repair and improvement of
cardiac function through tissue engineering that provide
new scientific insights, but also propel forward the find-
ings to new therapeutic designs for clinical treatment.
To date, although cardiac tissue engineering has not
been absolutely ready for routine clinical applications,
autologous and allogeneic adult stem cell transplants
have been successfully in cardiac therapies with random-
ized clinical trials (RCTs) in some reported cases [9].
Therefore, engineering innovations hold promise to
shape research and treatment directions in the years to
come. Together with tissue-engineered hearts for trans-
plantation, current methods have been focused on stem
cell transplantation in which cells are seeded onto 3D
polymer scaffolds followed by electrical, mechanical or
chemical stimulation (heparin and hyaluronic acid) in
order to promote stem cell differentiation. Eventually,
the diseased and injured heart tissues are expected to re-
store [10–12]. However, the concerns of histocompatibil-
ity of regenerated cardiac cells and stem cell-derived
pro-arrhythmic substrates [13, 14] have limited the use
of stem cell-based therapies for human heart failure. Asle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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novel biomaterials have recently emerged as a promising
approach for cardiac repair [12]. Interestingly, recent
findings in molecular mechanisms during the develop-
mental stages of mammalian hearts have suggested that
new CMs may arise from existing CMs and progenitor
or stem cells at early stages of embryo and newborn de-
velopment [15–19]. Toward this end, stem cells, includ-
ing cardiac stem cells (CSCs) [20], embryonic stem cells
[21], bone marrow-derived mesenchymal stem cells [22],
and cord-derived mesenchymal stem cells [23] are essen-
tial materials for cell-based tissue engineering applica-
tions; which have already entered the clinical setting
with some challenges [24–26]. However, the capacity
and significance of adult mammalian cardiomyocytes
and CSCs regeneration remain controversial [27–30].
One of reasons is that specific stem cell markers that are
used to identified CSCs, such as c-KIT, are necessary but
not sufficient for their identification [31–33]. Recently,
Kretzschmar et al., have used single-cell mRNA sequen-
cing and genetic lineage tracing to interrogate existence
of CSCs with unbiased mouse models of proliferation
and they found that cycling cardiomyocytes only domin-
antly presented in the early postnatal growth phase [27,
32], while many noncardiac cell types mainly present in
damaged adult myocardium [27, 34]. Although the gene
expression profile was shown the same in both injury-
activated cardiac fibroblasts and neonatal cardiac fibro-
blasts under in an autocrine fashion, there is no evidence
of a latent CSC population [32]. Although the presence
of CSC population in adult hearts is still controversial,
differentiating other stem cells into mature cardiomyo-
cytes is attractive in cardiac therapies.
To get a high yield of mature cardiomyocytes, scaffold-
ing and its derivates of growth factor/stimulating devices
have been deployed as a support substrate for cell
growth and transplantation to the host tissue in regen-
erative medicine [35, 36]. For instance, cell alignment is
essential for cardiovascular tissues in order to maintain
the microarchitecture and biological functions; therefore,
various strategies have been developed to induce cardiac
cell alignment. Those methods include topographical
patterning (e.g., micro- and nano-grooves and aligned
nanofibers), chemical treatment (patterns with cell-
adhesive or repellent chemistries), controlled stress/
strain conditions (e.g., stretching, fluid shear stress, and
compression), and a combination of them [13, 14]. In its
early stage, tissue engineering research involving CMs
revolved around injection of differentiated stem cells
with the hope they would grow and synchronize with
the host [6]. However, it was found that these cells re-
quired environmental conditions which were biomimetic
to early cell growth conditions, in order to differentiate
and bind into a syncytium [15]. This could be pulsatileelectrical stimulation similar to native syncytium electric
fields [15], simultaneous electrical stimulation and cyclic
mechanical stretching [37], or any combination of these
with bioinspired antioxidant materials and other micro-
environment cues [12, 17], which can be optimized by
algorithms based on experimental datasets.
The recent rise of artificial intelligence, especially ma-
chine learning and deep learning, has paved the way for
a wide range of applications, and cardiac tissue engineer-
ing is not an exception. Machine learning (ML) aims to
develop algorithms that discover trends and patterns in
existing data and use this information to make predic-
tions on new data. ML has proven to be of great poten-
tial value in a variety of application domains, including
biological investigations and healthcare where accurate
analysis of biomedical data benefits early prediction and
detection of diseases [38]. ML encompasses a diverse set
of schemes by which a machine extracts certain features,
“learns” the pattern of features associated with a certain
group and then predicts the group based on feature pat-
terns of new samples. The ML methods are particularly
effective in situations where prediction involves large
data sets, especially datasets of terabyte or petabyte size
[39]. Specifically, ML algorithms can perform efficient
data training to identify relationships of inputs and out-
puts, although there are not typically intuitive interpreta-
tions for how hidden layers in these algorithms operate
[40]. However, in this field, it is still in the proof-of-
concept phase where structures and algorithms have
been focused in order to minimize or eliminate human
intervention in these processes. For example, ML has
been used for automated drug classification based on
contractility of human pluripotent stem cell-derived
engineered cardiac tissue [41], protein-ligand binding af-
finity [42], and histopathological image analysis [43]. Re-
garding 3D scaffold constructs, the fabrication could be
controlled and optimized with an adaptive neuro fuzzy
inference system and a Pareto-based self-learning evolu-
tionary algorithm [44].
In addition to many strategies for precision control of
myocardial microenvironment of smart biomaterial scaf-
fold for cellular adhesion, growth, and maturation [45,
46], ML and evolutionary algorithms have been used to
identify stemness features associated with oncogenic de-
differentiation [47], 3D scaffold design [48], local micro-
environment changes, and to drive cellular differentiation
pathways in CM maturation. Artificial intelligence-based
approaches, such as machine learning and deep learning,
refer to a set computer programs that deal with data train-
ing and perform intelligent analysis [49–51]. Machine
learning is an integration of algorithms such as naïve
Bayesian [52], support vector machines (SVM) and updat-
ing deep neural networks which are highly dependent on
high-quality data. ML with the model of end-to-end (E2E)
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sets created from high-throughput screening data for drug
discovery and development [53]. Recently, deep learning
as part of machine learning methods has catalyzed interest
for drug discovery [54]. Deep neural networks approaches
[55, 56] can process with all combinatorial variations using
the single E2E black-box network or the deep classifica-
tion network [57], which were deployed for biomedical re-
searches in cardiac contractile dysfunction and arrhythmia
[58, 59], facial phenotypes of genetic disorders [60], preci-
sion phenotyping and clinical diagnostic support systems
[53]. In tissue engineering field, it was reported that smart
scaffolds integrated with a wireless ML-driven sensing
responded to changes of electrophysiological phenotypes,
local tissue microenvironment (e.g. pH, protease activity,
and biosignatures) [61], and CM phenotyping (e.g. β-
Adrenergic receptor) [62, 63]. This may allow training the
data for self-repair approaches in the design of 3D scaf-
folds and cardiac regeneration. Moreover, ML allows per-
forming multifunction by controlling serial signals of the
biomimetic paracrine in custom design to identify cell
shape phenotypes associated with microenvironment cues
[64, 65]. Thus, novel ML-based scaffold designs may pro-
vide not only a robust substrate for cardiac tissue culture
but also a real-time database for precision bioactive con-
trol (e.g., timed release of growth factors) in the micro-
environment that may be required for improvements of
CM regeneration and repair.
In the next sections of this paper, molecular and bio-
material engineering approaches will be introduced and
discussed followed by methods for nano-scaffold fabrica-
tion. Updates of upcoming and ongoing ML applications
in tissue engineering, especially as it relates to cardiac
tissue engineering, will be then broadly covered.
Genome editing and stem cell differentiation
CRISPR/Cas systems for cardiac tissue engineering
Gene mutants in human cardiac failure
According to statistics, it was revealed that gene-related
factors and genetic variations are responsible for complex
forms of cardiovascular disease (CVD) [7]. For example,
genetic variants of missense mutations (T983I) in the
KCNH2 (LQT2) gene frequently relate to and arrhythmo-
genic disorders like QT syndrome [18]. Techniques using
induced pluripotent stem cells (iPSCs) and genome editing
can intervene at molecular levels for cell adhesion, differ-
entiation, and cell alignment in cardiac tissue engineering
[19, 66]. Genome editing based on programmable nucle-
ases is a molecular process that uses clustered regularly
interspaced short palindromic repeats systems (CRISPR)
with Caspase 9 (Cas9) guiding enzymes and has been used
to introduce the catecholaminergic polymorphic ventricu-
lar tachycardia type 1 (CPVT1) associated cardiac ryano-
dine receptor 2(RYR2) mutation in healthy wild iPSCs [19].In principle, CRISPR/Cas9 systems are nucleic acid-
targeting defensive tools of prokaryotes, whose operation is
exploited to edit mammalian genomic materials and con-
trol transcriptional regulation of endogenous genes; in
turn, these genes can be used to control molecular routines
in tissue regeneration [67]. By introducing F2483I RYR2
mutations to wild type human iPSCs (hiPSCs), calcium sig-
naling pathology can be observed and compared between
iPSC-derived CMs from CPVT1 patient cells and gene-
edited cells. Results show that increased diastolic Ca2+ and
reduced sarcoplasmic reticulum store size in gene-edited
and patient-derived CMs are consistent with each other
[19]. Alternatively, CRISPR/Cas9 engineered R453C-
βMHC [68] and corrected PRKAG2 mutations in patients
[69] allow them to recover physiological mitochondrial
functions, as well as electrophysiological and structural ab-
normalities, making this a reasonable approach to recover
CM functionality [68, 69].
Potential of CRISPR/Cas systems in cardiac tissue
engineering
The CRISPR/Cas9 system is based on two components: a
synthetic, single-stranded guide RNA (sgRNA) and Cas9
enzymes. The spacer part of the sgRNA can be designed to
bind complementary DNA targets for Cas9 cleavage at a
protospacer adjacent motif (PAM) in the DNA targets, in
order to generate a single-strand or double-strand break.
Subsequently, a new DNA is formed through one of the
two molecular mechanisms: non-homologous end joining
(NHEJ) or homology directed repair (HDR). These mecha-
nisms serve to introduce random mutations and to pre-
cisely edit DNA sequences, respectively [70]. However,
several challenges exist with the use of this system, such as
off-target effects and the difficulty in delivery of large Cas9
sequences. Off-target effects refer to nonspecific and mis-
matched genetic modifications that can arise using engi-
neered programmable nuclease techniques. In CRISPR/
Cas9 systems, these off-target effects can be resolved by re-
ducing non-specific binding of gRNA sequences. CRISPR/
Cas9 systems can be introduced to cells in the form of
plasmid DNA, RNA, or proteins, which can be used for
engineering cells in cardiac tissue regeneration [68, 71]. Re-
cently, Doudna et al. explored CasX enzymes risen from a
TnpB-type transposase, a distinct family of RNA-guided
genome editor (CRISPR/CasX), that can be used as a third
platform for RNA-programmed genome editing [72]. With
the compact size, dominant RNA content, and minimal
trans-cleavage activity, CasX is the smaller size compared
to that of the previous reported Cas9 and Cas12a. This
provides an increased efficiency of therapeutic delivery and
overcoming the human immune systems, which may offer
more advantages relative to current CRISPR/Cas systems.
CRISPR/Cas systems can be also utilized to reactivate non-
dividing cells and terminally differentiated mammalian
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architecture formation, both of which having been demon-
strated for cardiac stem cell engineering [67–69]. More-
over, due to difficulty in ex vivo culture of primary CMs, a
potential alternative approach is using a CRISPR/Cas9 sys-
tem to edit iPSCs-derived CMs in situ. These edited iPSCs
can differentiate into readily transplantable cells: iPSC-
cardiac progenitors or iPSC- derived CMs to deliver to the
diseased heart though intracoronary or intramyocardial
routes. As an example, iPSC-derived CMs have been
seeded on micro-threads then transferred to cardiac tissue
and contractile cardiac fibers [73]. Unfortunately, iPSC-
derived CMs are immature with regards to their structure
and function, and this immaturity has narrowed down
their applications in drug screening and cell-based therap-
ies [74]. One of solutions is to create the geometry of the
environment based on extracellular matrix (ECM) for cel-
lular behavior and maturation [75].
Attachment of CMs or iPSC-cardiac progenitors to cul-
ture systems is highly dependent on levels of fibronectin
and collagen IV in the extracellular matrix (ECM), both of
which feature prominently in cardiac cell fate [61]. With
the CRISPR/Cas9 system, the expression of those matrix
proteins can be increased, which improves cell homing
functions in culture systems. In another report, this editing
tool has been used to eliminate inactivated genes in mature
CMs through the Adeno-associated virus 9 (AAV9)-
sgRNAs system [76]; it has also been used for editing the
mitochondrial genome in order to control membrane po-
tential disruption and cell growth inhibition, which are
related to cancer genesis in transplanted tissues [40].
Moreover, the CRISPR/Cas9 system has been applied to
human stem cell-derived CMs for cardiovascular disease
modeling and cardiotoxicity screening; enabling studies of
new cardiovascular disease treatments and drug-induced
cardiotoxicity [77]. In addition, the CRISPR/Cas9 system
can address safety concerns by reducing immunogenicity
and even the risk of arrhythmia by removing the mutant
ryanodine receptor 2 (RYP2) from the multimeric com-
plexes [78]. To minimize the risk of immunogenicity, in
addition, the suicidal thymidine kinase gene can be in-
duced into the genome of stem cells for iPSCs and embry-
onic stem cells (ESCs) to efficiently protect hESC-derived
allografts from immune rejection [66, 79]. Molecular activ-
ities of ion channels and gap junctions determine the func-
tionally proficient electromechanical coupling between
myocardial cells. Defects in the molecular activities respon-
sible for restoring myocardial electrical conduction can be
mitigated by targeted genes [80] and macrophage cell ther-
apy [81]. Macrophages are innate immune cells that reside
and accumulate in the healthy and injured hearts. A com-
plex crosstalk between cardiomyocytes and macrophages
regulates the fate of cardiomyocytes in the injured heart
and plays central roles in cardiac hypertrophy [82].Given that the clear majority of heterogeneous CMs in
postnatal tissue is postmitotic, a new routine for homolo-
gous recombination of these cells is required. This begins
by analyzing the transcriptome during the differentiation
process of human PCSs to mature CMs in order to identify
a key transcriptional roadmap for molecular intervention
[35]. Interestingly, CRISPR/Cas9 systems can contribute to
cell differentiations by controlling the gene profile expres-
sion through Cas activity. Polstein et al. reported a light-
inducible CRISPR/Cas9 system to control endogenous gene
activation and transcription [83, 84]. Alternatively, CRISPR/
Cas9 systems provide direct benefits in controlling of im-
mune response for CM engraftment [85]. Since mature
CMs are postmitotic cells, they lack the HDR repairing
mechanism and the CRISPR/Cas9 system doesn’t work in
these cells. This restriction can be overcome with iPSC-
CMs from patients or endothelial cells (ECs), smooth
muscle, and cardiac progenitor cells in which genes of
interest are edited ex vivo. Then these cells can differentiate
to all cardiac lineages used for cardiac regeneration. In
addition, together with synthetic biology, bioinformatics,
and deep learning CRISPR/Cas9 systems are able to reduce
off-target consequences and create gene regulatory net-
works for multicellular development [61, 86]. Using
CRISPR/Cas9 systems to reprogram fibroblasts into skeletal
myocytes with the targeted activation of the endogenous
Myod1 gene locus results in elevated expression levels of
myogenic markers, mainly because activation is comparable
to a lentiviral vector-delivered MYOD1 transcription factor
[87]. With such an activation, in vivo CMs and other car-
diac lineages at injury sites can be converted from cardiac
resident fibroblasts. This process relates to the complex
multilayered regulatory systems that induce cell differenti-
ation and heart development as a system biology level [88].
Gene regulatory networks play an important role in the
spatiotemporal expression of desired cardiac regeneration-
related proteins. Products of this expression are involved
in many endogenous and exogenous physio-chemical stim-
uli, producing growth factors and other cytokines which
shape cardiac tissue structure. The GRN can be regulated
at molecular levels via the technique of synthetic biology
coupled with bioinformatics, in order to design biological
circuits and provide tools for more intricate control of cel-
lular functions. With such an approach, tissue regeneration
can overcome long-standing challenges and introduce new
methods for basic research and clinical applications. In
biosafety regulations, CRISPR/Cas9 system activity could
be eliminated to avoid risks of permanent expression of
foreign targets when designing tissue structures for clinical
use. Figure 1 introduces a protocol to edit mutant genes in
hiPSCs and monitor cardiac differentiation; which was
done with molecular and phenotypic characteristic meas-
urement. Briefly, CRISPR/Cas9 system was used to intro-
duce long-QT syndrome genes in independent healthy
Fig. 1 (1) Introduction of LQTS genes in independent healthy hPSC lines using CRISPR/Cas9. (2) Generation of disease-cardiomyocyte hiPSCs. (3) Isogenic
sets of hPSC-CMs were differentiated from the edited hiPSCs lines. (4) Molecular analysis and phenotyping of hPSC-CMs (upper) molecular pathogenesis,
(middle) drug screening, and (bottom) physiological functions
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in the formation of isogenic sets of hiPSC-CM which were
characterized with phenotyping and molecular analysis.
CRISPR/Cas9 systems for tissue-specific engineering of
stem cells not only provide new avenues for functional tis-
sue engineering and regenerative medicine, but also con-
trol the immunological balance in both the early and
chronic stages after cardiac injury [89]. Proinflammatory
cytokines present in increased levels in diseased and
injured tissues, which leads to the increase of tissue deg-
radation and can prevent differentiation of hiPSCs [90].
Recently, reports strongly suggested that controlling in-
flammatory cytokine secretion from resident cardiomyo-
cytes and cell interaction is one potential approach for
cardiac angiogenesis and cellular regeneration [91, 92].
Previous studies have reported that transplantation of
cells genetically engineered for constitutive overexpression
of interleukin 1 receptor antagonist (IL-1Ra) is effective
when creating cells-integrated scaffolds for implantation
[93]. This approach also provides great promise in combat-
ing inflammatory levels of interleukin 1 (IL-1), a challenge
for transplanted and/or engineered tissues. To this end,
RNA interference or CRISPR/Cas9 systems have been used
for controlling the expression of inflammatory cytokines
[43]. Alternatively, regulation of gene expression of growth
factors and anti-inflammatory cytokines (IL-4, IL-1Ra, and
IL-10) in cell-based engineering platforms are also aconsiderable approach. Compared to RNAi technology,
however, the CRISPR/Cas9 systems provide permanent re-
moval of inflammatory cytokines from the cell genome,
this guarantee long term control of anti-inflammation in
cardiac tissue regeneration.
Due to numerous challenges in current cardiac tissue re-
generation, the CRISPR/Cas9 system has become an effect-
ive alternative which can tackle those by providing
complex genome editing and transcription regulation, in
order to control differentiation, at genomic and molecular
levels [67, 70]. While still in its early stages, ongoing re-
search on the use of CRISPR/Cas9 systems for more-
complex implementation of the CM molecular clock [94]
by controlling the transcription-translation feedback loop
may be a milestone in tissue engineering. In brief, CRISPR/
Cas9 systems hold potentials to dramatically improve com-
prehension of cellular processes and contribute signifi-
cantly to cardiac tissue engineering.
Stem cell differentiation
Differentiation of stem-cell-derived CMs into the desired
lineages requires many aspects of the scaffold constructs,
cell fate, and cell’s environment [36, 73, 95–98]. Using
hiPSCs to differentiate into mature CMs has been consid-
ered as a potential approach towards therapeutics in car-
diac tissue generation. With optimal protocols, fetal
hiPSCs can be differentiated into almost 100% pure CMs.
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source of adult human cardiac myocyte for clinical thera-
peutics, they still lack many essential features such as be-
ing well-organized and distributed, and functional
transverse tubules (T-tubules) [99]. Chong et al. reported
that mature human ESC-derived CMs, rather than imma-
ture, may become the preferred candidate to reduce the
risk of arrhythmias in the transplantation therapy [100]. In
addition, adult-like hiPSC- derived CMs can be widely
used for applications in stem cell-based disease modeling
and in drug toxicity screening [95, 101]. Some strategies of
generating cardiac tissue from stem cell-derived CMs, in
which their cellular morphology is similar to human adult
cardiac structure and function, have been reported [74,
102, 103]. Ronaldson-Bouchard et al. used different stages
(day 12 and day 24 differentiation) of hiPSC-derived CMs
and co-cultured them with fibroblasts in a fibrin-based
hydrogel to grow mature cardiac tissues around two flex-
ible pillars [104]. These pillars were used to induce forces
in the contracting tissues, as forces are observed in native
myocardium. After 1 week in culture, either constant elec-
trical stimulation (2Hz for 3 weeks) or intensity training
(2 to 6 Hz ramp over 2 weeks, then back to 2 Hz for one
week) were applied to stimulate the differentiation and
growth of hiPSCs to maturize CMs, which were deter-
mined through the molecular, cellular, and functional level
of the differentiation [104, 105]. At the molecular level,
genes associated with adult-like conduction, atrial
isoform-related ventricular isoform of myosin, ATP
production, and calcium transportation were highly
expressed, which indicated maturation. At the cellular
level, growth of CMs with ordered sarcomeres and a high
density of mitochondria, were observed [104]. Vital pro-
teins such as T-tubules and folding of the sarcolemma
membrane, involved in calcium transportations, were
found in the cell [106, 107]. Cell alignment in tissue con-
structs, where cells were adhered to one another with
mechanical strength at gap junctions, promoted electrical
signaling transmission between cells in the constructs.
Well-aligned hiPSC-derived ventricular CMs on the hu-
man ventricular cardiac anisotropic sheet, a cardiomimetic
biohybrid material, was reported in fully key electrophysio-
logical features of native human ventricle [108]. This was
observed only when hiPSC-CMs received an intensity
training at an early stage [109]. After spending the inten-
sity training, cardiac tissues were able to efficiently
perform action potentials through a process of excitation-
contraction coupling. Electrical stimulation (excitation) in-
duces mechanical response (contraction), which allows
myocardium to contract. Wiegerinck et al. reported that
increased beating frequency was the simultaneous result
of increased contraction force and faster relaxation [110].
Various regulatory factors involved in CM maturation,
hormone-driven cues [99], intensive electrical stimulation[111, 112], cell composition and matrix/media [113, 114]
have shown the most potential to achieve hiPSC-derived
CMs in scaffold environments.
In cardiac tissue engineering, natural polymer scaffolds
play an important role in promoting differentiation and
growth of hiPSC-derived CMs owing to their minimal im-
munogenicity and biodegradability. Kaiser et al. used a
blended fibrin and collagen scaffold to differentiate
hiPSC-derived CMs into engineered myocardium [97]. Re-
sults showed that expression of cardiac troponin T (cTnT)
in CM populations were dependent on the scaffold com-
paction. While the decreased compaction showed the low-
est (24.4%) and highest (60.2%) positive expression of
cTnT+ CM purities, the highest compaction showed 40–
50% cTnT+ population [97]. This study clarifies the correl-
ation of hiPSC-derived CMs and scaffold interactions and
provides a basis for integrated design of customized scaf-
fold constructs for cardiac tissue engineering.
Biomaterials and 3D scaffold fabrication
Characteristics of biomaterials
Biomaterials in the forms of hydrogels, carriers, and scaf-
folds play a vital role in anchoring cells and helping them
generate into functional tissues [115–117]. Although those
forms have different specific patterns in tissue engineer-
ing, all of them serve as a framework substance for prolif-
eration and differentiation of the desired tissue. For
example, carrier materials enable cells or chondrons to
produce the ECM that holds growth factors in skin wound
healing and cardiac remodeling and repair [118, 119]. Por-
ous hydrogels entrap embedded cells and allow diffusion
of gas and metabolites through their pore network [120,
121]. Similarly, scaffolds are also porous matrices, though
they allow cell migration and attachment to the damaged
tissue, as well as act as a substitute for lost tissue in the
body [122]. The developing highly-porous scaffold bioma-
terials significantly depend on their types of materials,
functionalization, and geometry.
Typically, biomaterials for tissue engineering are synthe-
sized or modified from primary natural materials, then
further processes are conducted to form appropriate
morphology and characteristics for a desired application.
They include polyglycolic acid (PGA) [123], poly(L)-lactic
acid (PLA), poly(DL) glycolate (PLGA), and polyvinyl al-
cohol and their derivatives [124–126]. In contrast, natural
biomaterials include collagens, alginate, chitosan, fibrin
and hyaluronic acids. Recently, advances in synthetic
chemistry have contributed to novel hybrid biomaterials
with outstanding properties in terms of conductivity and
strength [127, 128]. For use in cardiac tissue engineering,
it is required for biomaterials to support tissue reconstruc-
tion and regeneration via active support for cell-to-tissue
processes by promoting cell-cell adhesion, proliferation
and differentiation. These biomaterials can also culture
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for gas and nutrient transportation as well as formation of
vascular supportive substructures for blood vessels. The
biomaterials used for scaffold fabrication processes can
optimize constructs used in clinical settings; allowing for
maximizing cellular adhesion space, ECM secretion, re-
vascularization, and paracrine processes.
Shaping biomaterials in 3D structures
Scaffold materials play a key role in tissue engineering
and have been used more and more in clinical practice
[129–131]. These materials form a biomimetic ECM
which promotes cell adhesion and differentiation, as well
as 3D organotypic cultures [132]. By combining modern
advances of three major fabrication techniques, namely
electrospinning, self-assembled monolayers, and ther-
mally induced phase separation, with peptides and DNA,
biomimetic 3D scaffolds have been developed for CM
regeneration [133–135]. These systems support differen-
tiation of various stem cells down multiple lineages and
create relevant 3D specific tissues for clinical practice.
Obviously, specific cell types could be seeded on the
biomimetic nanofibrous scaffold to regenerate desired tis-
sues. Both primary and stem cells can be used, for differ-
ent purposes [36, 98, 112]. Primary cells are collected
directly from mature tissue and cultured to obtain the de-
sired cell number and form tissue constructs. However,
quick phenotypic changes, limited proliferation numbers,
and aging of primary cells inhibit their use once the cells
are transferred from their natural living conditions to arti-
ficial ones [132, 136]. While CMs can be taken from spe-
cific tissue sources for targeted applications, robust
scaffolds and engineered biological tissues are needed to
improve to CM characteristics in new implanting environ-
ments. Most scaffolds used for cardiac tissue engineering
are hydrogel materials and 3D nanofiber matrices, which
feature benefits such as controlled release of growth fac-
tors and good electrical conductivity [137, 138]. Results
from confocal laser scanning microscopy, scanning probe
nano-tomography, and transmission electron microscopy
show that cardiac cells and fibroblasts actively interact
with 3D nanofibrous substrates, but in different ways
[139]. While fibroblasts make contact with nanofibers
through focal adhesion clusters, without wrapping the
fiber, CMs develop a distinguished sheath structure and
covering fiber to increase contact area [139, 140]. These
results point to a new perspective on how cultured cells
interact with 3D nanofibrous scaffolds. A host of previous
studies reported that matrix anisotropy and stiffness pre-
dominantly influence 3D structural cell phenotypes, cell
migration, proliferation, and differentiation of cultured
CMs [141]. Cardiac cells grown in 3D matrices were
always in tight contact with each other through cellular
junctions, which results in considerable mechanicaladhesion between cardiac cells and fibers. The increase in
mechanical adhesion was found to be linked with the in-
creased contact area between the cells and fibrous struc-
tures [142]. The contact area plays a role for focal
adhesion kinase in cardiac mitochondrial biogenesis in-
duced by mechanical stress, which contributes to the
hypertrophic growth of cardiomyocytes via control of
mitochondrial transcription cascade [143].
Cellular parameters like the number of mitochondria
and endoplasmic reticulum membranes featured higher
counts of cells grown in 2D constructs. Moreover, Wobma
and colleagues reported that upgraded “smart” scaffolds
can directly control biologically active molecules like hor-
mones in the paracrine pathways directly through the cell
membrane, avoiding dissipation through the whole tissue
solution [144]. In such a system, bioactive molecules are
efficiently used for CMs because they increase the diffu-
sion of these molecules from neighboring cells through
paracrine hormones. It is also helpful if conducting mate-
rials are integrated into these platforms prior to cardiac
cell regeneration. Fibers are immersed in cardiac cells to
promote high densities of electrical contacts, thus forming
an electrical network on the outer part of the nanofibrous
structures isolated from the surrounding integrin micro-
domains. With currently-available biomimetic models
[129], the physical basis for this could be explained with
van der Waals forces and DLVO theory. DLVO theory is
the typical explanation of the stability of colloids in sus-
pension [145]. The explanation of the cell interaction sta-
bility is governed by physical and chemical interactions
between cellular surfaces that the balance between two
opposing forces-electrostatic repulsion and van der Waals
attraction is under DLVO theory [146, 147]. The inter-
action energy is calculated by the sum of van der Waal
forces and electric repulsion energy; thus zeta potential,
hydrodynamic diameter, and cellular surface thermo-
dynamic properties play an important role in the inter-
action energy in the scaffold microenvironment for cell
alignment and elongation [148].
Model of generation, alignment, and stabilization of spin-
dle shaped fibroblasts and vessel under oscillatory stretch
was also reported [149]. These results reveal a new mech-
anism for vessel network formation: under oscillatory
strain, 3D scaffolds can promote mural cell alignment, cell
proliferation, translocation of a mechanosensitive transcrip-
tional activator (YAP) into cell nuclei, and increased ex-
pression levels of β-catenin. This directs ECM alignment
along the orientation of the fibroblasts. Furthermore, ECs,
which are tolerant to stretch stimulus, form aligned vessels
directed by the fibroblast and ECM alignment. However,
there is loss of fibroblast alignment and vessel alignment
due to mechanical uncoupling of the cells after adding
blebbistatin to the culture medium [149]. In addition, both
fibroblasts and vessels lose alignment when the cellular
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anical stimulus are inhibited. Stretch stimulus promotes the
stable production of growth factors, which enhances mural
cell differentiation, thereby enriching stability and align-
ment. These findings demonstrate how increased mechan-
ical strain affects cell development, differentiation, and
shape formation during the vascularization process. Cellu-
lar stretching is restricted by nucleus size, which is less sen-
sitive to deformation [139]. At the adhesive site, the cell is
stretched by surface tension force. Absorbing fibers is not
energetically beneficial in the case of the actin cytoskeleton,
hence contact is minimized with fibers by reduction of cell
membrane surface area [150]. Thus, these cells are able to
generate enough forces to overcome the resistance of the
actin cortex at several filament assembly complex locations.
In contrast to fibroblasts, CMs contain integrins in costa-
mere structures that anchor sarcomeres to the ECM, so
myocytes have much higher affinity with the substrate and
serve to stabilize areas of cell-ECM interaction. Therefore,
when CMs grow on suspended fibers, the myofibrils start
attaching and aligning with them to increase the area of
interaction with the substrate [139].
The 3D microenvironment increases adherence and dir-
ect reprogramming of fibroblasts into CMs throughout
the matrix via a metalloproteinase dependent mechanism
[151]. The nanofibrous poly(L-lactide) (PLLA) scaffolds
adsorb serum proteins and ECM proteins like fibronectin,
vitronectin, and laminin at quantities four times higher
than solid walled PLLA scaffolds [151, 152]. In nanofi-
brous form, the absorption of protein is influenced by
many surface characteristics such as protein absorption
layers, surface-to-volume ratio, surface nm-scale morph-
ology, crystallinity, and orientation of the polymer in its
nanofibrous form. Finally, nanofibrous scaffolds promote
cell adhesion in many cell types, giving them an advantage
over solid walled scaffolds.
3D-gel of hybrid biomaterials
Natural biomaterials can be produced from self-assembled
monolayers (SAM) of different polymers through hydrogen
bonds, van der Waals forces, and hydrophobic and electro-
static interactions [153]. SAM fabrication is very useful
and robust, thus some recent studies have attempted to
mimic collagen structures from ECM-derived binding pep-
tides, which increased cell adhesion and cardiac repair by
cardiac progenitor cells [154]. These systems can work
with other self-assembling materials like phage display
peptides and genetic materials to improve adhesion, prolif-
eration, and controlled differentiation; rendering many ap-
plications in tissue engineering [155]. Wang et al. reported
a procedure to fabricate biomaterials for 3D scaffold for-
mation based on SAMs from bacteriophage display [156].
In this approach, a panel of desired peptides was displayed
on M13 phages, a bacteriophage of Escherichia coli, for thepurpose of CM generation by activating ligand-linked mi-
croenvironments in damaged cardiac tissues (Fig. 2) [150].
As seen in Fig. 2, RGD and DLEFIFEER ligand motifs that
mediate adhesion to the cell adhesive receptors were dis-
played on major coat protein pVIII and determined
through an interaction between nephronectin and α8β1 in-
tegrin receptor [158]. Using a 3D printer, assembly of the
short peptide-coated nanoparticles into a 3D functional
structure was driven by noncovalent interactions to form a
scaffold [158]. The mechanisms of these self-assembled
processes have led to major advances in the understanding
of biological and chemical 3D folding processes for bio-
mimetic supramolecular peptide assemblies in coatings,
gels and electroactive materials. The specific function of
these materials relies on their helical peptides, β strand
peptides, and surface binding monolayer-forming peptides,
which electrically stabilized the phage nanofiber inside the
RGD-phage scaffold. Subsequently, hiPSCs were seeded in
the RGD-phage scaffold and induced the formation of car-
diomyocytes [159].
The geometry of the scaffold substrate is very important
in cardiovascular tissue engineering because the cardiac
tissues need to be highly differentiated to perform high
specific functionality. For example, the microscopic level
of heart valve needs to be at anisotropic geometry, in
order to have particular shape of semilunar valves at the
macroscopic level [160]. Microenvironment and contrac-
tion properties of cardiomyocytes can be influenced by
morphology and mechanical properties by increasing the
modulus in the range of 1–30 kPa of 2D substrates [161].
Developing these properties in synthetic 3D scaffold may
provide a significant means of controlling cell fate both
in vitro and in vivo. An ideal polyester biomaterial elasto-
mer for cardiac tissue engineering should exhibits a
relatively-low Young’s modulus, with high elongation and
tensile strength [162]. Through a one-step polycondensa-
tion reaction and ultraviolet reaction, poly(octamethylene
maleate (anhydride) 1,2,4-butanetricarboxylate) (124 poly-
mer) is formed the prepolymer gel and a cross-linked
elastomer with highly elastic and tunable properties [162],
of which they are dependent on the UV light exposure,
monomer composition, and porosity of the cured elasto-
mer. Interestingly, the material does not only provide its
elastomeric properties falling within the range of those of
adult heart myocardium, but also is optimized for higher
elasticity for cardiac cell attachment and interaction
in vitro and in vivo [162]. Finally, the polymer expressed
relatively-stable degradation characteristics that support
potential tissue implants. Recently, Shiekh et al. developed
and evaluated an elastomeric antioxidant polyurethane
(PUAO) for cardiomyocyte functionality [12]. A serial ana-
lysis including uniaxial and cyclic tensile testing, thermal
analysis, cytotoxicity, antioxidant analysis, and degrad-
ation reveals that PUAO reduces intracellular oxidative
Fig. 2 (See legend on next page.)
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Fig. 2 Biomaterials are based on self-assembled monolayers from bacteriophage display for 3D scaffolds formation. (Top), RGD peptide is
displayed and fused to the solvent-exposed terminal of each copy of major coat protein (pVIII) through genetic engineering. The side wall of
filamentous phage by RGD-coding gene into gene VIII to generate RGD-phage. (Bottom) The 3D scaffold of RGD-phage nanofibers (negatively
charged) self-assemblies with polycationic biomaterials and integrated into a 3D printed bio-ceramic scaffold [156], which electrically stabilizes the
phage nanofiber inside the scaffold. The resulted scaffold is seeded with hiPSCs and the implanted into cardiac defect. The presence of RGD-
phage in the scaffold induced the formation of cardiomyocytes [157]
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oxygen species (ROS) promoted cell death. Moreover,
PUAO film displayed synchronous beating with mature
cardiomyocytes showing high expression of cardiac spe-
cific α-actinin, troponin-T, and connexin-43 proteins [12].
Additionally, cultured cardiomyocytes on PUAO film
expressed the physiological intracellular calcium function-
ality similar to mature cardiomyocytes [12].
Shin et al. used directed SAM to selectively trap target
carbon nanotubes (CNTs) as an effort to control the
growth of supramolecular hydrogel fibers and improve
functionality of bioengineered cardiac tissues [117]. Sur-
faces of CNTs stimulate the formation of hydrogelators in
the vicinity of the fiber constructs, which results in in-
creased fiber formation, changes in network morphology,
and increased mechanical properties. Subsequently, this
can improve electrophysiological performance of cardiac
tissue in terms of increased beating rate and lower excita-
tion threshold [117, 163]. Besides CNTs, metallic nanopar-
ticles, with their size-dependent properties, have shown
promise in overcoming many of the current limits of car-
diac tissue engineering. Li et al. reported a nanocomposite
composed of gold nanoparticles (AuNPs) and a collagen
matrix, which improved tissue growth via localized
strength, thus enhancing the assembly of intercalated discs
by β1-integrin-mediated signals [151]. In addition, 3D
structures based on rigid CNTs scaffolds have been used to
improve CMs viability, proliferation, and maturation, but
they require undesirable invasive surgeries for implantation
[164]. On the platform of 3D gel-based matrix, an inject-
able reverse thermal gel (RTG) functionalized with CNTs
(RTG-CNT) that switches their morphology from a so-
lution at room temperature to a three-dimensional (3D)
gel-based matrix shortly after reaching body
temperature was developed [164]. This extends long-
term CMs survival, promotes CMs alignment and pro-
liferation, or improves CM physiological function. Re-
cently, Mason et al. reported a highly-ordered 3D
fibrous protein scaffold derived from a self-assembly
processes [153]. This resulted from a balanced system of
low-entropy processes in which a set of interactions
between different chain residues formed amorphous ag-
gregates, thus mimicking self-assembling protein sys-
tems in nature. As an alternative to self-assembly,
electrospinning produces nanofibers and nanofibrous
structures from a broad range of biomaterials-baseddopes in which advantages, drawbacks and potential ap-
plications are discussed in next sections.
Electrospinning for 3D scaffold fabrication
Electrospinning could be used to make nanofibers from a
variety of polymers and it is well suited to 3D nano-
scaffold constructs in cardiac tissue engineering [165]. In
essence, the electrospinning technique is based on an elec-
tric field to create a charge on the surface of polymer solu-
tions, thus generating a force opposing its surface tension
and allowing fibers to be drawn out [166]. Many parame-
ters can be used to tune this process, including electrical
charges from the jet, solvent characteristics, length of
polymers, flow rates, voltage levels, and collector distance;
all of these considerations, and others, need to be taken
into account to get a final polymer fiber in nanofibrous
architecture [167, 168]. The resulting products are col-
lected on solid or liquid substrates, or even substrate free,
to form 3D micro-fibrous and nanofibrous scaffolds.
Suhaeri et al. reported a new platform based on a
fibroblast-derived, matrix-coupled, aligned and electro-
spun nanofiber [45]. In their work, a hybrid scaffold
structure composed of poly(l-lactide-co-caprolactone)
(PLLA-PCL) and fibroblast-derived ECM (PLLA-PCL/
FDM) was aligned to form an artificial cardiac microenvir-
onment. The physical mechanical property of PLLA-PCL
in the parallel direction shows the anisotropic nature of
the aligned PLLA-PCL fibers. The PLLA-PCL/FDM was
produced from the fibroblast culture on the PLLA-PCL
fiber for 5–7 days and the ECM was collected from a sub-
sequent decellularization. On this co-culture system, cel-
lular characteristics of differentiation, phenotyping, cell
viability, and maturation of H9c2 and neonatal rat CMs
were significantly improved compared to those in fibro-
nectin (FN)-coated electro-spun PLLA-PCL fibers (Fig. 3)
[45]. On the aligned scaffold, cells spread along the direc-
tional cues instead of the random growth in every
direction observed in the random scaffold. In addition,
non-sulfated polysaccharides [169], biopolymers [170],
and both organic and inorganic frameworks [171] have
been integrated into PLGA to improve its biocompatibility
and mechanical properties; and this highly depends on
polymer concentration. However, due to collector plate
constructs, nanofibrous scaffolds made from electrospin-
ning are generally 2D; limiting their clinical relevance. Re-
cently, a rotating cylinder has been demonstrated as a
ab
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Fig. 3 Fabrication and characterization of PLCL/FDM. a Illustration represents the fabrication process of PLCL/FDM. b Random and aligned orientations of
PLCL fibers. Scale bar of SEM images is 10 μm. c Fibrillary ECM components in FDM were stained against FN and collagen type I. The direction of PLCL
fiber alignment is shown by double headed arrows. Scale bar is 50 μm. d ATR-FTIR spectra of FDM with C=O at 1753 cm− 1 from PLCL and amide group at
1645 cm− 1 from FDM. e AFM images for surface topographical features of PLCL and PLCL/FDM; color scale shows their surface roughness and difference
in height. f Quantitative comparison of root mean square (RMS) roughness calculated from AFM images. Statistical significance (***p< 0.001). The
reproduced image is permitted from [45]
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ning, which was utilized to produce a tubular scaffold and
allow for growth factors to be released in a controllable
fashion [172, 173]. A scaffold platform with polyca-
prolactone (PCL) nanofibers and vascular endothelial
growth factor (VEGF)-encapsulated gelatin particles
was fabricated to extend half-life time and stimula-
tions of VEGF to mesenchymal stem cells (MSCs)
and ECs [174]. In addition, paracrine mechanisms
that are involved in MSC differentiation into cardio-
myocytes are only limited to cell differentiation rates,
not directly impacting to cell differentiation [175,
176]. Jiang et al. reported that this construct can
drive the differentiation of MSCs to ECs and keep the
stability of the tubular structure [174], indicating that
growth factor (GF)-releasing scaffolds are potential
platforms based on the electrospinning process for
cardiac tissue engineering.Recently, it has been shown that use of a Teas chart
could provide useful information in terms of solubility
and spin-ability for the electrospinning process [177–179].
Polymers should have solubility in the target condition, as
values outside of a specific range will result in electro-
sprayed beads and aggregates [177]. Higher fidelity nano-
scale topography and bio-activity integration in the 3D
architecture on the ECM-inspired nanofibrous scaffolds
showed outstanding advantages for engineering 3D aniso-
tropic cardiac tissues [137, 180].
Thermally-induced phase separation
Thermally induced phase separation (TIPS) is another
robust method to make 3D scaffolds. It involves five
steps: polymer preparation, phase separation and gel-
ation, solvent extraction, freezing, and freeze drying
[181]. Once a polymer is dissolved in a specific solvent,
the solution becomes thermodynamically unstable and
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another phase “lean” in polymer. The resultant polymer
structure depends on the ratio of polymer to solvent and
conditions of the phase separation. Once the solvent is
extracted, the phase of lean polymer is removed, and the
polymer rich phase is identified as being in one of three
categories: powder, closed cell foam, and open cell foam.
Open cell foam is the type used to make 3D scaffolds for
human chondrocyte growth and ECM formation [182].
ECM-derived porous foams are biologically-relevant
substrates in advanced 3D in vitro cell culture models
through controlling freezing and lyophilization proce-
dures [183].
Luca et al. reported the formation of surface structures
of TIPS-based scaffolds formed in water at room
temperature [184]. The TIPS method allows for tuning
of surface morphology which benefit tissue regeneration
of preosteoblasts [184]. Peña et al. presented an inject-
able and biomimetic RTG that was functionalized with
poly-L-lysine or laminin to promote longevity of cul-
tured CMs, neonatal rat ventricular myocytes (NRVM),
and adult rat ventricular myocytes (ARVM) [130]. Their
results showed that the RTG functionalized with lysine
stimulated NRVM grow and differentiated heart-like
functional syncytia. Beating cells were recorded after 21
days in both cases of RTG and Lysin-functionalized
RTG [130]. In addition, TIPS can be combined with
porogen leaching to increase levels of architectural con-
trol. Porogen leaching (paraffin, sugar) can promote the
formation of micropores with morphologies such as
spherical, tubular, and disk shaped pores within the scaf-
fold [185]. These micropores play important roles in en-
hanced cell penetration, proliferation, mass transport of
nutrients, and growth factors in studies of angiogenesis
and tissue formation. Several research groups have de-
veloped anatomically shaped molds with reverse solid
freeform fabrication (SFF) in a PLLA solution [186, 187].
Architectural features were formed through three steps:
ECM-mimicking materials, formation of pores for cell
penetration and mass transport, and anatomical scaffold
shaping. This last step is vital for structural tissue like
bone and cartilage. TIPS can be used in concert with
porogen leaching and 3D molds and with common
chemical and biological polymers to create structural tis-
sue scaffolds with excellent processing flexibility.
Bioprinting for 3D scaffolds
Advancements in 3D printing have now begun to see its
use in tissue engineering. State-of-the-art techniques in
this field includes laser direct writing and multiphoton
polymerization, which can be used for computer-aided
scaffold design [188]. The process of designing and manu-
facturing scaffolds in this way includes several steps: de-
sign of functionally graded scaffolds, modeling of selectivelaser sintering and fused deposition modeling (FDM) pro-
cesses, development of bioreactors, and 3D bioprinting
[188–190]. Laser systems such as femtosecond- and
ultraviolet-based sources allow for precise manufacture of
3D tissue scaffolds, which are engineered entirely through
computer-aided design [191]. Zheng et al. reported the
process of using computer-controlled UV laser systems
for 3D scaffolds with many kinds of polymers such as
polyethylene glycol diacrylate (PEG-DA), ormocomp, pen-
taerythritol tetra-acrylate (PETRA) [192]. More recently, a
class of micro-architected materials with high-ordered
structural connectivity and nanoscale features was printed
by projection micro-stereolithography [192]. By using bio-
polymers, the technique could be used to produce bio-
compatible micro-lattices for soft tissue engineering,
which are used as injectable scaffolds that can either in-
duce endogenous cardiomyocyte repairing [193].
Seeded cardiomyocytes can be grown in hexagonal 3D
fiber scaffolds made by melt electro-writing, a form of 3D
printing. The resultant hexagonal microstructures have
outstanding mechanical characteristics, allowing for large
anisotropic reversible deformations; this deformable struc-
ture mimics microstructure of myocardial tissue [137].
Moreover, the high porosity of these structures aids for-
mation of aligned tissues and are effective as cardiac
patches on contracting hearts. These functional human
myocardial patches feature properties highly desirable for
clinically relevant cardiac repair [96]. As a result, iPSC-
derived CMs have been successfully cultured in multi-
cellular 3D bioprinting substrates for vascularized heart
tissue [98]. Human umbilical vein endothelial cells
(HUVECs) and iPSC-CMs have been encapsulated within
hydrogel strands, containing alginate and PEG-fibrinogen,
and forced out through custom microfluidic printing
heads to form spatial depositions with high fidelity and
resolution. Maiullari and colleagues have reported a 3D
cardiac tissue composed of iPSC-CMs from different tai-
lored geometries with a high orientation index [98]. Blood
vessel-like shapes differentiated from HUVECs can be
used for in vivo grafting, which is a better integrated sup-
port for engineered cardiac tissue [98]. These findings also
bring important contributions to functional heart tissue
generation in vitro through 3D PEG-fibrinogen hydrogels
to recover their pluripotency [98]. This technique plays a
key role in the design of printed micro-fibrous constructs
used to assemble complex vascular networks. For ex-
ample, bio-printed ECs following this can effectively de-
velop vasculature in the transplanted tissues in the same
manner of native vessels [194]. The results of bio-printed
3D vessel-based therapy directed to restore blood flow
can counteract cell death and promote regeneration in the
revascularization of ischemic or damaged organs, which
highly relies on microenvironment engineering for sup-
plies of oxygen and nutrient.
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sion (in the 100–200 μm scale) in porous structures, mi-
gration of iPSCs tends to be in the outer zone of
hydrogels; and this produces inhomogeneous cellular
distribution in vascular networks in vivo [195, 196].
These diffusion problems could be solved via an inte-
grated system of porous structures and parallel fibers to
form an engineered vascular network. By addition of 1%
w/w PEG-DA monomer to bioprinting materials, the
homogeneous culture biosystem fully supplies nutrients
to all regions of the 3D constructs [98] . This technique
has been used for iPSC-derived CMs culture to produce
myocardial-like tissue [98] and generate 3D vascular
structure [197]. Alternatively, circulation in the 3D con-
structs is supplied by a microfluidic device bearing a Y-
junction (2 inlets, 1 outlet) in which the flows of two
different bio-inks are precisely driven by external micro-
fluidic pump [98]. Interestingly, this construct showed
great promise for artificial skeletal muscle generation
once the dimensions of channel were reduced to 500 ×
500 μm2 (cross-section) to create an extremely-small
dead volume (< 2 μL); this allowed rapid tuning be-
tween the two bio-inks during printing. This system
also allows building heterogeneous structures compos-
ing of iPSC-derived CM and HUVEC could poten-
tially mimic native cardiac contraction in better than
those described above.
Functional contraction of the myocardium is orches-
trated by electrical stimulation propagation in the right
sequence and is driven partially by CM spatial orienta-
tion; therefore, proper orientation is a critical goal for
organization of CMs [98, 159]. The organization of CMs
embedded in 3D bio-printed fiber structures is impacted
by the surrounding fiber matrix direction; often, growth
of iPSC-derived CMs is directed along the fiber printing
direction. Contraction can be further enhanced with
higher material conductivities. Scaffolds that couple
electrical and elastic materials have become valuable
for cardiac cell function, but current conductive ma-
terials do not show tunable physiological properties
for cell behaviors [138, 198]. Electrospun conductive
scaffolds were reported of use in cardiac tissue engin-
eering for enhancement of connexin 43 expression
[96, 198]. By integration of AuNPs into hydrogel scaf-
folds, the polymer templated gel becomes tunable
with a Young’s modulus similar to that of myocar-
dium, polyaniline, and polypyrrole. Neonatal rat CMs
were cultured on the scaffold and expressed high
level of connexin 43, with or without electrical stimu-
lation. Hosoyama et al. have also reported a novel
nanoengineered hybrid electro-conductive cardiac
patch for treating the infarcted myocardium [96] of
which classification and localization from medical im-
ages are detected by machine learning [199–203].Machine learning and precision control for 3D
scaffold fabrication
Machine learning in tissue platform
As mentioned, currently the most obvious use of ma-
chine learning (ML) in this field is identifying patterns in
tissue-related data and/or classifying specific tissue con-
structs. One example of a problem of interest is that of
classifying the phenotype of differentiated, stem cell-
derived CMs. One group sought to classify CM pheno-
type by matching distinct groups of shapes with distinct
groups of action potential waveforms [204]. It was done
by staining the cells of interest, optically mapping them
during contraction, converting time-varying pixel inten-
sity to discrete waveforms, and then using ML algo-
rithms to identify groupings of AP behavior which they
could compare to cell cluster shape data. The employed
ML is what’s known as spectral clustering whose algo-
rithm attempts to minimize a “similarity” weight value
between sets of inputs, thereby grouping them [205]. In
this case, the authors used aligned and averaged AP as
the input to the clustering algorithm, allowing the algo-
rithm to minimize similarities between groups of the AP
waveforms, and then mapped these groupings to cell
cluster spatial distributions. These methods have been
successfully applied in biomedicine and cell biology with
various stage-of-the-art machine-learning algorithms
[58, 60, 206].
A more-recent example of ML used in this space was
geared toward not only classification of cardiac tissue
contractile events [207] but extending this classification
set into a predictive model for preclinical screening ef-
fects of drugs on cardiomyocyte function [41]. The pre-
dictive models are highly dependent on machine
learning methods such as naïve Bayesian, support vector
machines (SVM), and end-to-end (E2E)-integrated ML
system [53], of which they are leveraged by bigger data-
sets generated from high-throughput screening data. Lee
et al. reported a SVM to develop a drug screening assay
on hiPSCs-derived cardiac tissue (Fig. 4) [41]. In this ap-
proach, groups of linearly separable data were demar-
cated by planes in order to classify them [208]; and the
planes themselves were statistical maximizations of
group separation based on feature points (i.e. support
vectors), rather than the more-computationally intensive
nearest-neighbor piecewise approach [209].
They first qualified models by generating force data
and derived parameters from stimulated cardiac cells,
mixing the data with a control set, allowing a binary
SVM to attempt to classify the data, and then quantify-
ing the resulting SVM accuracy [210]. This classification
model accuracy then becomes a proxy for cardiac activ-
ity of the drug. About 50% accuracy means that the
SVM could not separate control from drug but accuracy
greater than 50% indicates that the statistical model was
Fig. 4 Machine learning for drug screening on human iPSCs-derived engineered cardiac tissue. a Waveform pattern parameters are determined
based on concentration of cardioactive compounds compared to the binary support vector machine (SVM). The collected data points would be
in line with those of vehicle as if the compound does not modulate the contractile behavior of human ventricular cardiac tissue strips (hvCTSs). If
data of cardio active effects are more distinguishable, it shows in a higher SVM accuracy which is possible to separate two compound groups.
The degree of cardio activity of a given concentration for target compound is shown in a singular quantitative index with the binary SVM
approach. b Library of compounds is built on a model for prediction of mechanistic action of screened compounds. Data from the library group
allow the machine learning defines boundaries of various drug families. Finally, the developed model can be applied for the unknown
compounds on tissue engineering. The image is reproduced with permission from [41]
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regions of the parameter space and, therefore, declare a
difference in behavior [41, 211]. Data of cardio active ef-
fects express in a higher SVM accuracy, if they are more
distinguishable from two compound groups. Based on a
given concentration, the degree of cardio activity for a
target compound is shown in a singular quantitativeindex with the binary SVM approach [41, 207]. Next, a
library of this drug screen testing data was combined
and an SVM designed for multiple classes was used to
define parameter space regions for each. The library of
compounds was built on a multiple-category prediction
model for mechanistic action of screened compounds
and chemogenomic databases [212, 213]. Data from the
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aries of various drug families and mechanism of action
[214]. Finally, the developed model can be applied for the
unknown compounds on tissue engineering. After doing
so, a withheld data set of the same form was fed into their
predictive model to see if the SVM could properly classify
drug interactions [215], integrating multiple omics data
[216], and unknown drug compounds [217]. In their dem-
onstration, they were able to classify cardiac activity of un-
known compounds with an accuracy of roughly 72% and
generalize the results to other drug families with an accur-
acy above 70% [218]. Further, ML and its myriad algo-
rithms can also be used on the protein and gene side of
tissue engineering, as it has been demonstrated or pro-
posed for histopathological image analysis [43], ligand af-
finity [42], folding structure [219], gene expression and
biomarker data mining [220, 221], and in evaluation of
pre-implantation embryos [222]. Large datasets such as
the “Tissue Atlas” [223], a human proteome map catego-
rized by tissue, could easily be used as a training and test-
ing set for ML algorithms targeting identification of
impaired tissue or disease onset.
Precision control in fabrication of 3D scaffold
The ever-widening and accelerating field of robotics
both contributes to and has the possibility of benefitting
from tissue engineering. The contribution of robotics to
tissues engineering lies mostly in the manufacturing
space; as automated fabrication has hastened tissue con-
struct research. Of particular popularity at the moment
is the concept of robotic bio-fabrication, also known as
organ printing or bioprinting. Bioprinting was defined
by members of the first international workshop on the
subject in 2004 as the “use of material transfer processes
for patterning and assembling biologically relevant mate-
rials—molecules, cells, tissues, and biodegradable bio-
materials—with a prescribed organization to accomplish
one or more biological functions” [224]. In other words,
it’s the use of automated fabrication to faster transfer
from the scaffold design and tissue culture, to clinical
settings, especially in the field around regenerative
cardiomyocytes.
As discussed earlier, 2D and 3D cardiomyocyte cultures
in biomimetic conditions are crucial to the improvement
of knowledge surrounding cardiac tissue development
[225]. Researchers have presented methods for forming
these tissue constructs in a variety of manners— from
using electrospinning to create scaffolds enabling cell at-
tachment and growth [96] to 3D patterning of tissue-
similar constructs [226], or using printer deposited
spheroids to induce scaffold-less self-assembly of tissue
[227, 228], although some of these technologies have sig-
nificant hurdles to overcome still. Within the last decade,
researchers have begun to concern themselves with thesystems design of holistic industrial bio-fabrication lines,
including the design stage prior to and maturation stage
after bio-fabrication [229]. In-vivo bio-fabrication is also
getting attention; beyond bioresorbable printed scaffolds
[230], there have even been demonstrations in mice of
laser printing of photoactive resins above the calvaria to
form bone-like caps [230], which was integrated with the
robotic controlling.
Tissue engineering is also feeding back into robotics in
two important ways—inspiring bio-mimetic robotic sys-
tems [231] and becoming a potential component within
robots themselves [232]. Most bio-similar robots up to
this point have focused on the use of soft materials to
grip and move, as the field has acknowledged that the
limited conformability of robotics prior to this trend is
directly counter to the variety of conformable structures
seen in nature [231]. Much of the interest in artificial
tissue has been focused on muscle. One group demon-
strated artificial muscle composed of polymer-based
composites which bend and flex under cation exchange
[233], similar to action potential propagation in cardiac
tissue. Another group demonstrated this same concept
using a collagen gel filled with rat CMs and initiated
contractile behavior strictly chemically, using epineph-
rine and nifedipine [234]. This is somewhere between
the former and latter contributions of tissue engineering
but there are recent examples in which robotics systems
have been designed from the systems level to take
advantages of engineered tissues, themselves being bio-
similar robotic systems. As an example of engineered
tissue integrated robotics, researchers have demon-
strated actuators which are comprised of myoblast-
filled hydrogels and triggered by electrical stimulation
[235], antagonistically contracting against each other
to create both contraction and extension. It is of note
here that not only are the actuators themselves engi-
neered tissues, but they have been attached to their
skeletal frame by culturing methods, and even the
mechanical systems design mimics natural tissue. It is
likely that more bio-similar, bio-integrated robotic hy-
brids are on the horizon.
Conclusions
Cardiac tissue engineering has benefited greatly from ad-
vances in genetic engineering, material engineering, elec-
trical engineering, and biochip design. Within genetic
engineering, genome editing is a pioneering tool that has
been used in the generation of new cellular, tissue and
animal models to investigate cell-cell adhesion, differen-
tiation of hiPSCs, and generation of CMs for various
cardiac disease. However, the post-mitotic nature of
CMs and various technical barriers present hurdles for
bringing engineered cardiac tissue directly to therapeutic
applications. Other cells such as cardiac fibroblasts, ECs,
Nguyen et al. Journal of Biological Engineering           (2019) 13:57 Page 16 of 21and muscle cells can potentially substitute for CMs in
developing tissues for cardiovascular diseases.
One major technical advancement in this field is the abil-
ity to design a physical framework of biocompatible mate-
rials and the control of mechanical characteristics, which
can be applied clinically. Due to the nature of CMs, scaffolds
used for CM growth should be readily tunable for align-
ment/organization to produce efficient contractions. Further,
electrical stimulation should be integrated into the system to
perform intensity training in the later stages of CM culture
[111]. This enables the connection of native and differenti-
ated cells, at single cell levels of cellular communications,
between hiPSC and CMs. Communication between CMs
and their micro-environment within the engineered tissue
should be understood in tandem with development of 3D
biomimetic scaffolds and bioreactors in order to promote
cost-effective scale-up of tissue production.
There exists a variety of supporting technologies which
could be applied in the process of tissue engineering. One
possibility is that machine learning be used involved in the
design and processing of micro-physiological systems.
High-throughput fabrication could be optimized via scaf-
fold geometry, cellular paracrine factors, and cellular com-
munication, in order to maximize survival rates and
completely functionalize engineered cardiac tissue. At the
molecular and cellular level, engineered cardiac tissue de-
rived from the HLA-null line should be tailored towards
developing immune-resistant modified hiPSC-derived CM
lines; this can be done using genome editing tools focused
on solving cryopreservation general implantation issues.
Confucius said, “Our greatest glory is not in never fail-
ing, but in rising every time we fail.” We believe with
focused and continued progress achieved by scientists
across a range of multidisciplinary fields, cardiac tissue
engineering will soon be viable for clinical use.
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